Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study

  • Salvinia Mletzko, David J. Pinato, Rebecca C. Robey, Alessia Dalla Pria, Peter Benson, Nesrina Imami, Mark Bower
  • OncoImmunology, April 2017, Taylor & Francis
  • DOI: 10.1080/2162402x.2017.1304337

The authors haven't yet claimed this publication.

Read Publication